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1. Introduction
  The staphylococcal toxic shock syndrome (TSS) is a fatal 
infectious disease caused by the enterotoxins (toxic shock 
syndrome toxin-1 (TSST-1) and other toxins) released by 
Staphylococcus aureus (S. aureus). The exotoxin serves as 
a superantigen, which directly interacts with the invariant 
region of the class II MHC molecule, thereby activating large 
numbers of T cells, often up to 20% of all T cells at a time. 
This results in massive cytokine production[1]. Released 
cytokines including interleukin (IL)-1, IL-2, tumour 
necrosis factors (TNF)-毩 and -毬 and interferon (IFN)-毭
cause the symptoms of TSS. Clinical manifestations are 
often characterized by fever, rash (erythema)/desquamation 
(1-2 weeks after the onset of rash) and hypotension. 
Furthermore, TSS causes multisystem involvement including 
that of GI, muscular, mucous membrane, renal, hepatic, 
haematological and central nervous systems. The majority 
of cases of staphylococcal TSS are caused by methicillin-
susceptible S. aureus (MSSA). However, as rates of 
infection due to methicillin-resistant S. aureus (MRSA) have 
increased, the number of cases of TSS due to MRSA have 
also increased[2,3].
  Half of all TSS cases are not reported to be associated with 
menstruation[4,5]. Non-menstrual TSS has been observed in 
a wide variety of clinical settings including postoperative 
and postpartum wound infections, sinusitis, respiratory 
infections following influenza, mastitis, osteomyelitis, 
arthritis, burns, cutaneous/subcutaneous lesions and 
enterocolitis[6-13]. Postoperative cases increased from 14% in 
1979-1986 to 27% in 1987-1996[14]. 
  Patient fatalities have been attributed to cardiac problems 
(arrhythmias and cardiomyopathy), respiratory failure or 
DIC. Mortality due to non-menstrual TSS is higher than 
that in menstrual cases (5% versus 1.8%)[14,15]. Death usually 
occurs within the first few days, but in some cases it occurs 
15 d after hospital admission[16,17].
2. Case report
  A previously healthy 46-year-old baseball player with 
no remarkable past medical or family history, no known 
drug allergy and no prior medications was referred to our 
hospital by an orthopaedic surgeon. The patient presented 
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with fever, hypotension and watery diarrhoea. He had 
smoked for 28 pack-years and consumed 500 mL of beer 
per day. Three weeks before, he had undergone orthopaedic 
surgery because of left fibular and tibial fracture during a 
baseball game. Open reduction and internal fixation (ORIF) 
and fasciotomy were performed to treat his fracture and the 
compartment syndrome that occurred concurrently. Two 
weeks before, fasciorrhaphy was performed successfully. 
However, the next day the patient passed loose brownish 
stools; his blood pressure dropped to 60 mmHg (systolic 
blood pressure), and fever rose to 39 曟. Blood tests revealed 
BUN to be 50 mg/dL and Cr to be 2.5 mg/dL. The patient was 
referred to our hospital. He had taken cefazolin for 2 weeks 
after surgery.
  On examination, the vital signs of the patient were as 
follows: blood pressure, 70/48 mmHg; heart rate, 107 beat 
per min; body temperature, 39.0 曟; respiratory rate, 24 and 
SpO2, 95% in ambient air. Diffuse macular erythema was 
observed on the trunk (Figure 1), extremities and face. The 
left leg was markedly swollen, with the presence of warmth 
and redness and the surgical scar (Figure 2). External Juglar 
vein collapse was evident even in the supine position. Other 
physical findings were unremarkable. His blood test results 
were as follows: WBC 189 800/毺L, Hb 11.1 g/dL, Ht 30.5%, 
Plt 11.2×104/毺L, T-P 5.1 g/dL, Alb 2.3 g/dL, AST 136 IU/L,
ALT 71 IU/L, T-bil 1.5 mg/dL, LDH 452 IU/L, CPK 5 026 IU/
L, ALP 43 IU/L, GGT 14IU/L, Amy 103 IU/L, UN 53 mg/dL, 
Cr 2.5 mg/dL, BS 121 mg/dL, Na 129 mEq/L, K 4.0 mEq/L, Cl 
96 mEq/L, CRP 23.0 mg/dL, FDP 40.8 mg/dL, FIB 339 mg/dL, 
D-dimer 26.5 毺g/mL. An X-ray of the left lower extremity 
revealed no gas collection beneath the soft tissue.
Figure 1. Diffuse macular erythema was found on his trunk.
Figure 2. Left leg was markedly swollen with warmth and redness 
with surgical scar.
  On the basis of his clinical manifestations, the patient 
was diagnosed with TSS. Aggressive fluid replacement 
therapy (infused fluid volume, 5-8 L/d for the first 3 d) with 
administration of vancomycin (1 g) and ceftriaxone (2 g) 
plus clindamycin (1 200 mg qd) were immediately initiated. 
Surgical inspection was performed, but no necrotic tissue 
was observed. Local drainage was performed.
  After supportive antibiotic therapy, TSS symptoms resolved. 
One week later, desquamation was complete. Two weeks 
after the day of admission, the patient was stabilised and 
discharged from the hospital. A culture of the wound tissue 
revealed MRSA with positive TSST-1.
3. Discussion
  Sex distribution was equal in a study of 130 TSS cases 
in which vaginal and postpartum-associated cases 
were excluded[18]. Patients with non-menstrual TSS are 
significantly older (mean age, 26.8 years versus 23 years 
in patients with menstrual TSS) and more often non-white 
compared with patients with menstrual TSS[5,11,18]. The 
case-fatality rate for non-menstrual TSS was reported to 
be 5% and did not decrease over time[14]. TSST-1 was the 
first exotoxin isolated from S. aureus in TSS in 1981[19,20]. 
It is found in over 90% of menstrual TSS cases and in 40%-
60% of strains from non-menstrual cases. Our patient was a 
middle-aged Asian male suffering from postoperative TSS 
caused by TSST-1.
  The diagnosis of TSS is established based on clinical 
presentation that satisfies the CDC case definition[21,22]: 
patients must have fever >38.9 曟, hypotension, diffuse 
erythema, desquamation (unless the patient dies before 
desquamation can occur) and involvement of at least three 
organ systems. A probable case is defined as a patient who 
is missing one of the characteristics of the confirmed case 
definition. Our patient satisfied all the aforementioned 
criteria with GI, muscular, renal and hepatic involvement. 
Eighty to ninety percent of TSS patients have S. aureus 
isolated from mucosal or wound sites, while this is not 
required for the diagnosis of staphylococcal TSS[23]. On 
the other hand, S. aureus is rarely isolated (5%) from blood 
cultures compared with streptococcal TSS[18]. In our patient, 
S. aureus was isolated from the wound site, and not from 
blood cultures.
  The mainstay of treatment for TSS is supportive, while the 
patient presents hypotension. Rapid fluid replacement and/
or vasopressors are also necessary. In addition to supportive 
therapy, removal, drainage or debridement of any possible 
infectious focus is imperative. Exploration of surgical 
wounds is important for patients with postoperative TSS 
because signs of infection may be masked because of the 
decreased inflammatory response.
  Whether antibiotics alter the course of acute TSS remains 
unclear although antibiotic therapy has been revealed to 
reduce the likelihood of recurrent TSS by eliminating the 
carrier state[23]. Clindamycin plus either vancomycin or 
linezolid may typically be administered to patients with TSS 
due to MRSA for 10-14 d even in the absence of overt S. aureus
infection. Clindamycin is a pivotal and efficacious drug for a 
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drained postoperative infected focus, acting by suppressing 
bacterial protein synthesis[24]. Vancomycin and linezolid 
are effective drugs for treating MRSA. In our patient, 
vancomycin and ceftriaxone were administered in addition 
to clindamycin at the beginning of the therapy because it 
was uncertain whether the causative agent was Streptococcus 
or Staphylococcus. Hence, we covered both of the organisms 
since TSS is the fatal condition and the dual coverage should 
be required unless the causative organism is uncertain.
  Intravenous immunoglobulin (IVIG) therapy has been 
suggested in severe cases that have been recognized early 
in their course and have not responded to supportive 
therapy[25]. However, no controlled trials of IVIG therapy in 
staphylococcal TSS have been conducted in humans[25,26]. 
On the other hand, IVIG treatment may be efficacious in 
streptococcal TSS[27,28]. A report from Sweden noted that 
culture supernatants containing the superantigen from 
S. aureus were less efficiently inhibited by IVIG than 
those from S. pyogenes[29]. Another additional therapy 
corticosteroid is not recommended because of the limited 
clinical evidence with this therapy. We did not use both of 
IVIG and corticosteroids in our case.
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